Minitran 15 (Glyceryl Trinitrate)

Glyceryl trinitrate releases nitric oxide after skin absorption. Nitric oxide activates guanylate cyclase, increasing cyclic GMP in vascular smooth muscle, which leads to vasodilation of veins and arteries, lowering cardiac preload and afterload and relieving angina.

The prescribed dose of Minitran 15 is determined by the treating physician based on the patient’s clinical condition. The patch delivers 15 mg of glyceryl trinitrate over a 24‑hour period, and the healthcare professional decides the frequency of patch changes.

The safety of Minitran 15 in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Minitran 15, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Minitran 15 provides continuous nitrate delivery via a transdermal system, which can improve adherence compared with multiple daily oral nitrate tablets. Unlike short‑acting nitrates, the patch offers steadier plasma levels, but it shares class‑related side effects such as headache and hypotension.

Store Minitran 15 at room temperature, below 25 °C, in its original packaging. Keep the patches away from moisture, direct sunlight and heat sources. Do not expose the patch to temperatures above the recommended range, as this may affect drug stability.

Minitran 15 is applied to clean, dry, hair‑free skin on the upper torso or upper arm. The patch is worn for 24 hours and then removed and replaced with a new one at a different site to minimise skin irritation.

The most serious risks include severe hypotension, syncope, and rare allergic reactions such as anaphylaxis. Patients should be instructed to rise slowly, monitor blood pressure, and seek immediate medical attention if they experience fainting, severe dizziness or signs of an allergic response.

Minitran 15 should not be used by patients with known hypersensitivity to glyceryl trinitrate or any nitrate, those taking phosphodiesterase‑5 inhibitors, or individuals with severe anemia, increased intracranial pressure, or uncompensated heart failure unless specifically advised by a physician.